Vincamine
Structural formula | ||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
General | ||||||||||||||||||||||
Non-proprietary name | Vincamine | |||||||||||||||||||||
other names |
|
|||||||||||||||||||||
Molecular formula | C 21 H 26 N 2 O 3 | |||||||||||||||||||||
Brief description |
yellow crystals |
|||||||||||||||||||||
External identifiers / databases | ||||||||||||||||||||||
|
||||||||||||||||||||||
Drug information | ||||||||||||||||||||||
ATC code | ||||||||||||||||||||||
Drug class |
Peripheral vasodilator |
|||||||||||||||||||||
properties | ||||||||||||||||||||||
Molar mass | 354.44 g · mol -1 | |||||||||||||||||||||
Physical state |
firmly |
|||||||||||||||||||||
Melting point |
232 ° C |
|||||||||||||||||||||
safety instructions | ||||||||||||||||||||||
|
||||||||||||||||||||||
Toxicological data | ||||||||||||||||||||||
As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions . |
Vincamine is a compound from the natural group of alkaloids . It is used as a medicinal substance and can also be produced synthetically.
Occurrence
With a share of 25 to 65% of the total alkaloid content, vincamine is the main alkaloid of the small periwinkle .
Analytics
For secure qualitative and quantitative determination of the vincamine come after adequate sample preparation chromatographic methods such. B. thin layer chromatography , HPLC and gas chromatography , also in combination with mass spectrometry . The analytical methods mentioned are also used in studies of the metabolism of vincamine.
Pharmacological properties
Vincamine is said to have a beneficial effect on the brain metabolism by improving the blood flow in the brain and increasing oxygen uptake and glucose supply.
Vincamine penetrates the blood-brain barrier and has a strong tendency to bind to the brain tissue proteins. The binding to plasma proteins is 30%. The elimination half- life is approximately 6 hours.
Clinical information
application areas
Vincamine is used for cerebral circulatory disorders and brain performance disorders (slight age-related impaired brain performance), circulatory disorders in the eye and inner ear, and Menière's disease . A therapeutic benefit for brain disorders is considered insufficiently proven.
Side effects
Side effects reported include gastrointestinal disorders, drop in blood pressure, cardiac arrhythmias , restlessness and dry mouth.
Other Information
Finished medicinal products containing vincamine ( pervincamine retard and others) have not been on the market in Germany since 2005, due to the expiry of the fictitious approval . In Switzerland, Vivamin was on the market as Oxygeron .
Vincamine is a monoterpene - indole alkaloid from Eburnamin type. Along with vincristine , vinblastine and vindoline, it belongs to the vinca alkaloids .
Vincamine is the starting material for the synthesis of Vinpocetine .
Individual evidence
- ↑ a b c T. Dingermann, K. Hiller, G. Schneider, I. Zündorf: Schneider drug drugs. 5th edition. Elsevier, 2004, ISBN 3-8274-1481-4 .
- ↑ a b c d Datasheet Vincamine from Sigma-Aldrich , accessed on April 25, 2011 ( PDF ).
- ↑ R. Na, L. Jiajia, Y. Dongliang, P. Yingzi, H. Juan, L. Xiong, Z. Nana, Z. Jing, L. Yitian: Indentification of vincamine indole alkaloids producing endophytic fungi isolated from Nerium indicum, Apocynaceae. In: Microbiol Res. 192, Nov 2016, pp. 114-121, Review. PMID 27664729 .
- ↑ A. Akhgari, I. Laakso, T. Seppänen-Laakso, T. Yrjönen, H. Vuorela, KM Oksman-Caldentey, H. Rischer: Determination of terpenoid indole alkaloids in hairy roots of Rhazya stricta (Apocynaceae) by GC-MS . In: Phytochem Anal. 26 (5), Sep-Oct 2015, pp. 331–338. PMID 26095837 .
- ↑ V. Viganò, p Paracchini, G. Piacenza, E. Pesce: Metabolism of Vincamine in the rat. In: Farmaco Sci. 33 (8), Aug 1978, pp. 583-594. Italian. PMID 744256 .
- ↑ technical information Oxygeron (Drossapharm), as of May of 2006.